--- title: 联系Profil的Dr. Tim Heise description: 与Profil的Dr. Tim Heise取得联系。 --- [![Profil Logo](https://info.profil.com/hs-fs/hub/481167/file-2427498648.png?width=500&name=file-2427498648.png "Profil Logo")](https://www.profil.com?hsLang=zh) [![Contact](https://no-cache.hubspot.com/cta/default/481167/1f89c7d1-107f-4c8d-aa7b-f85d0dce14da.png)](https://cta-redirect.hubspot.com/cta/redirect/481167/1f89c7d1-107f-4c8d-aa7b-f85d0dce14da) [Patient information](https://www.profil.de) ![Contact our experts header](https://info.profil.com/hs-fs/hubfs/BLUE_MOON/Header/Header_1077x260px_About_Profil.jpg?width=1077&name=Header_1077x260px_About_Profil.jpg "Contact our experts header") # 认识和联系Profil的专家 ![Tim_Hexagon_154x176](https://info.profil.com/hs-fs/hubfs/Mitarbeiter/Tim_Hexagon_154x176.png?width=154&height=175&name=Tim_Hexagon_154x176.png) ### Tim Heise 博士 首席科学家 Tim是Profil的联合创始人及首席科学家。他是您在以下领域的联系人: - 胰岛素类似物 - 药效学 - 临床开发咨询 ### 简介 Tim在糖尿病和肥胖症的临床研究以及临床护理领域拥有超过25年的经验。他发表了250多篇关于胰岛素和抗糖尿病药物药理学的学术论文及评论。Heise博士是《糖尿病、肥胖与代谢》期刊编委会成员，他重点关注的领域是循证医学。 ### 发表物 以下是Tim的近期发表物:   - Heise T. [The future of insulin therapy.](https://pubmed.ncbi.nlm.nih.gov/33865915)  DIABETES RES CLIN PRACT 2021 Apr 16; 175:108820. doi:10.1016/j.diabres.2021.108820. Online ahead of print - Moser O, Riddell MC, Eckstein ML, Adolfsson P, Rabasa-Lhoret R, van den Boom L, Gillard P, Norgaard K, Oliver NS, Zaharieva DP, Battelino T, de Beaufort C, Bergenstal RM, Buckingham B, Cengiz E, Deeb A, Heise T, Heller S, Kowalski AJ, Leelarathna L, Mathieu C, Stettler C, Tauschmann M, Thabit H, Wilmot EG, Sourij H, Smart CE, Jacobs PG, Bracken RM, Mader JK. [Glucose monitoring for exercise using continuous glucose monitoring: should sex and prandial state be additional requirements? Reply to Yardley JE and Sigal RJ (letter)](https://pubmed.ncbi.nlm.nih.gov/33538843/)DIABETOLOGIA 64: 935-938, 2021  - Benesch C, Kuhlenkötter M, Nosek L, Heise T. [New Clamp-PID Algorithm for automated glucose clamps improves clamp quality.](https://pubmed.ncbi.nlm.nih.gov/33563051) J Diabetes Sci Technol 2021 Feb 10. doi: 10.1177/1932296821991514 - Albrektsson H, Heise T, Polonsky W. [Sustained intensive treatment and long-term effects on HbA1c reduction (SILVER Study) by CGM in people with type 1 diabetes treated with MDI. ](https://pubmed.ncbi.nlm.nih.gov/33199470) DIABETES CARE 44: 141-149, 2021 - Lind M, Olafsdottir AF, Hirsch IB, Bolinder J, Dahlqvist S, Pivodic A, Hellman J, Wijkman M, Schwarcz E, Albrektsson H, Heise T, Polonsky W. [Sustained intensive treatment and long-term effects on HbA1c reduction (SILVER Study) by CGM in people with type 1 diabetes treated with MDI. ](https://pubmed.ncbi.nlm.nih.gov/33199470) DIABETES CARE 44: 141-149, 2021 - Herbrand T, Coester HV, Sansone R, Fischer A, Heiss C, Heise T, Kelm M, DeVries HJ. [Improving the assessment of flow-mediated dilation through detection of peak time in healthy subjects and subjects with type 2 diabetes. ](https://pubmed.ncbi.nlm.nih.gov/33380161/) ANGIOLOGY 2020 Dec 30. doi: 10.1177/0003319720984884. Online ahead of print - Lind M, Olafsdottir AF, Hirsch IB, Bolinder J, Dahlqvist S, Pivodic A, Hellman J, Wijkman M, Schwarcz E, Albrektsson H, Heise T, Polonsky W. [Sustained intensive treatment and long-term effects on HbA1c reduction (SILVER Study) by CGM in people with type 1 diabetes treated with MDI.](https://pubmed.ncbi.nlm.nih.gov/33199470) DIABETES CARE 44: 141-149, 2021 - Andersen G, Meiffren G, Famulla S, Heise T, Ranson A, Seroussi C, Eloy R, Gaudier M, Charvet R, Chan Y-P, Soula O, DeVries JH. [ADO09, a co-formulation of the amylin-analog pramlintide and the insulin analog A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes (T1D).](https://pubmed.ncbi.nlm.nih.gov/33336850) DIABETES OBES METAB 2020 Dec 18. doi: 10.1111/dom.14302. Online ahead of print.  - Lind M, Olafsdottir AF, Hirsch IB, Bolinder J, Dahlqvist S, Pivodic A, Hellman J, Wijkman M, Schwarcz E, Albrektsson H, Heise T, Polonsky W. [Sustained intensive treatment and long-term effects on HbA1c reduction (SILVER Study) by CGM in people with type 1 diabetes treated with MDI.](https://pubmed.ncbi.nlm.nih.gov/33199470) DIABETES CARE 44: 141-149, 2021 - Eckstein ML. Boufleur Farinha J, McCarthy O, West DJ, Yardley JE, Bally L, Zueger T, Stettler C, Boff W, Reischak-Oliveira A, Riddell MC, Zaharieva DP, Pieber TR, Müller A, Birnbaumer P, Aziz F, Brugnara L, Haahr H, Zijlstra E, Heise T, Sourij H, Roden M, Hofmann P, Bracken RM, Pesta D, Moser O.  [Differences in physiological responses to cardiopulmonary exercise testing in adults with and without type 1 diabetes: A pooled analysis.](https://pubmed.ncbi.nlm.nih.gov/33184152) DIABETES CARE 2020 Nov 12. doi: 10.2337/dc20-1496. Online ahead of print. - Stegbauer C, Falivena C, Moreno A, Hentschel A, Rosenmöller M, Heise T, Szecsenyi J, Schliess F. [Costs and its drivers for diabetes mellitus type 2 patients in France and Germany: a systematic review of economic studies.](https://pubmed.ncbi.nlm.nih.gov/33198734/) BMC HEALTH SERVICES RESEARCH 2020 Nov 16; 20(1): 1043. - Moser O, Riddell MC, Eckstein ML, Adolfsson P, Rabasa-Lhoret R, van den Boom L, Gillard P, Norgaard K, Oliver NS, Zaharieva DP, Battelino T, de Beaufort C, Bergenstal RM, Buckingham B, Cengiz E, Deeb A, Heise T, Heller S, Kowalski A, Leelarathna L, Mathieu C, Stettler C, Tauschmann M, Thabit H, Wilmot EG, Sourij H, Smart CE, Jacobs PG, Bracken RM, Mader JK. [Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA).](https://pubmed.ncbi.nlm.nih.gov/33047169/) DIABETOLOGIA 2020 Oct 13. doi: 10.1007/s00125-020-05263-9. Online ahead of print - Seyed Ahmadi S, Westman K, Pivodic A, Olafsdottir AF, Dahlqvist S, Hirsch IB, Hellman J, Ekelund M, Heise T, Polonsky W, Wijkman M, Schwarcz E, Lind M. [The association between HbA1c and time in hypoglycemia during CGM and self-monitoring of blood glucose in people with type 1 diabetes and multiple daily insulin injections: A randomized clinical trial (GOLD-4).](https://pubmed.ncbi.nlm.nih.gov/32641374) DIABETES CARE 2020 Jul 8. doi: 10.2337/dc-19-2606. Online ahead of print - Leohr J, Dellva MA, Coutant DE, LaBell E, Heise T, Andersen G, Zijlstra E, Hermanski L, Nosek L, Linnebjerg H. [Pharmacokinetics and glucodynamics of ultra rapid lispro (URLi) versus Humalog (lispro) in patients with type 2 diabetes mellitus: A phase I randomised, crossover study.](https://pubmed.ncbi.nlm.nih.gov/32468448) Clin Pharmacokinet 2020 May 29. doi: 10.1007/s40262-020-00901-2. Online ahead of print - Heise T, Linnebjerg H, Coutant D, LaBell E, Zijlstra E, Kapitza C, Bue-Valleskey J, Zhang Q, Dellva MA, Leohr J. [Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogs: A Phase 1 randomized, crossover study.](https://pubmed.ncbi.nlm.nih.gov/32436641) DIABETES OBES METAB 2020 May 21. doi: 10.1111/dom.14094. Online ahead of print - Heise T, Donnelly C, Barve A, Aubonnet P. [Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL-1501D with US and EU insulin glargine formulations in patients with type 1 diabetes mellitus.](https://www.ncbi.nlm.nih.gov/pubmed/31724253) DIABETES OBES METAB 2019 Nov 13. doi: 10.1111/dom.13919. (Epub ahead of print) - Haahr H, Heise T. [Fast-acting insulin aspart: A review of its pharmacokinetic and pharmacodynamic properties and clinical consequences.](https://www.ncbi.nlm.nih.gov/pubmed/31667789) CLIN PHARMACOKINET 2019 Oct 30. doi: 10.1007/s40262-019-00834-5  - Parker VER, Robertson D, Wang T, Hornigold DC, Petrone M, Cooper AT, Posch MG, Heise T, Plum-Moerschel L, Heike S, Klaus B, Ambery PD, Meier JJ, Hirshberg B. [Efficacy, safety, and mechanistic insights of cotadutide a dual receptor glucagon-like peptide-1 and glucagon agonist.](https://www.ncbi.nlm.nih.gov/pubmed/31608926) J CLIN ENDOCRINOL METAB 2019 Oct 14. doi: 10.1210/clinem/dgz047. (Epub ahead of print) - Halberg IB, Lyby K, Wassermann K, Heise T, Plum-Mörschel L, Zijlstra E. [The effect of food intake on the pharmacokinetics of oral basal insulin: A randomised crossover trial in healthy male subjects.](https://www.ncbi.nlm.nih.gov/pubmed/31093929) CLIN PHARMACOKINET 2019 May 16. doi: 10.1007/s40262-019-00772-2. (Epub ahead of print) - Meiffren G, Herbrand T, Anastassiadis E, Klein O, DeVries JH, Heise T, Alluis B, Megret C, Gaudier M, Soula O, Plum-Mörschel L. [Better glycemic control with BioChaperone Combo (BC Combo) than with insulin lispro Mix25 (LMix) or separate glargine & lispro (G+L) administrations after a test meal in subjects with type 2 diabetes (T2DM).](https://www.ncbi.nlm.nih.gov/pubmed/30828929) DIABETES OBES METAB 2019 Mar 3. doi: 10.1111/dom.13685. (Epub ahead of print) - Halberg IB, Lyby K, Wassermann K, Heise T, Zijlstra E, Plum-Mörschel L. [Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial.](https://www.ncbi.nlm.nih.gov/pubmed/30679095) LANCET DIABETES ENDOCRINOL 2019 Jan 21. doi: 10.1016/S2213-8587(18)30372-3. (Epub ahead of print) - Schloot NC, Hood RC, Corrigan SM, Panek RL, Heise T. [Concentrated insulins in current clinical practice.](https://www.ncbi.nlm.nih.gov/pubmed/30583034) DIABETES RES CLIN PRACT 2018 Dec 21; 148: 93-101. doi: 10.1016/j.diabres.2018.12.007. (Epub ahead of print) - Heise T, Meiffren G, Alluis B, Seroussi C, Ranson A, Arrubla J, Correia J, Gaudier M, Soula O, Soula R, DeVries JH, Klein O, Bode B. [BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study.](https://www.ncbi.nlm.nih.gov/pubmed/30565407) DIABETES OBES METAB 2018 Dec 18. doi: 10.1111/dom. 13621. (Epub ahead of print) - Haahr H, Pieber TR, Mathieu C, Gondolf T, Shiramoto M, Erichsen L, Heise T. Clinical pharmacology of fast-acting insulin aspart versus insulin aspart measured as free or total insulin aspart and the relation to anti-insulin aspart antibody levels in subjects with type 1 diabetes mellitus. CLINICAL PHARMACOKINETICS 2018 Nov 7. doi: 10.1007/s40262-018-0718-6 - Hövelmann U, Braendholt Olsen M, Mouritzen U, Lamers D, Kronshage B, Heise T. [Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.](https://www.ncbi.nlm.nih.gov/pubmed/30350477) DIABETES OBES METAB 2018 Oct 23. doi: 10.1111/dom.13562. (Epub ahead of print) - Al-Qaissi A, Papageorgiou M, Javed Z, Heise T, Rigby AS, Garrett AT, Hepburn D, Kilpatrick ES, Atkin SL, Sathayapalan T. [Environmental effects of ambient temperature and relative humidity on insulin pharmacodynamics in adults with type 1 diabetes mellitus.](https://www.ncbi.nlm.nih.gov/pubmed/30311402) DIABETES OBES METAB 2018 Oct 12. doi: 10.1111/dom.13555. (Epub ahead of print) - Benesch C, Kuhlenkötter M, Heise T. [Considering blood dilution improves the precision of continuous whole blood glucose measurements.](https://www.ncbi.nlm.nih.gov/pubmed/30255710) J DIABETES SCI TECHNOL 2018 Sep 26. doi: 10.1177/1932296818803621. (Epub ahead of print) - Schliess F, Heise T, Benesch C, Mianowska B, Stegbauer C, Broge B, Gillard P, Binkley G, Crone V, Carlier S, Delval C, Petkov A, Beck JP, Lodwig V, Gurdala M, Szecsenyi J, Rosenmöller M, Cypryk K, Mathieu C, Renard E, Heinemann L. [Artificial pancreas systems for people with type 2 diabetes: Conception and design of the European CLOSE project.](https://www.ncbi.nlm.nih.gov/pubmed/30241444) J Diabetes Sci Technol 2018 Sep 21. doi: 10.1177/1932296818803588. (Epub ahead of print) - Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, Jermutus L. [MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.](https://www.ncbi.nlm.nih.gov/pubmed/29945727) Lancet 2018 Jun 30; 391: 2607-2618.  - Heise T, Heckermann S, DeVries JH. [Variability of insulin degludec and glargine U300: A matter of methodology or just marketing?](https://www.ncbi.nlm.nih.gov/pubmed/29770552) DIABETES OBES METAB 2018 May 17. doi: 10.1111/dom.13365. (Epub ahead of print) - Andersen G, Meiffren G, Lamers D, DeVries JH, Ranson A, Seroussi C, Alluis B, Gaudier M, Soula O, Heise T. [Ultra-rapid BioChaperone Lispro improves post-prandial blood glucose excursions versus insulin lispro in a 14-day crossover treatment study in patients with type 1 diabetes.](https://www.ncbi.nlm.nih.gov/pubmed/29923294) DIABETES OBES METAB 20: 2627-2632, 2018 - Forst T, Alghdban MK, Fischer A, Weber MM, Voswinkel S, Heise T, Kapitza C, Plum-Mörschel L. [Sequential treatment escalation with dapagliflozin and saxagliptin improves beta cell function in type 2 diabetic patients on previous metformin treatment: An exploratory mechanistic study.](https://www.ncbi.nlm.nih.gov/pubmed/29727906) HORM METAB RES 2018 May 4. doi: 10.1055/a-0591-9442. (Epub ahead of print) - Moser O, Eckstein ML, McCarthy O, Deere R, Bain SC, Haahr HL, Zijlstra E, Heise T, Bracken RM. [Heart rate dynamics during cardio-pulmonary exercise testing are associated with glycemic control in individuals with type 1 diabetes.](https://www.ncbi.nlm.nih.gov/pubmed/29608593) PLOS ONE 2018 Apr 2. doi: 10.1371/journal.pone.0194750. eCollection 2018. - Olafsdottir AF, Polonsky W, Bolinder J, Hirsch IB, Dahlqvist S, Wedel H, Nyström T, Wijkman M, Schwarcz E, Hellman J, Heise T, Lind M. [A randomized clinical trial of the effect of continuous glucose monitoring on nocturnal hypoglycemia, daytime hypoglycemia, glycemic variability, and hypoglycemia confidence in persons with type 1 diabetes treated with multiple daily insulin injections (GOLD-3).](https://www.ncbi.nlm.nih.gov/pubmed/29608107) DIABETES TECHNOL THER 20: 274-284, 2018 - Stinkens R, van der Kolk BW, Jordan J, Jax T, Engeli S, Heise T, Jocken JW, May M, Schindler C, Havekes B, Schaper N, Albrecht D, Kaiser S, Hartmann N, Letzkus M, Langenickel TH, Goossens GH, Blaak EE. [The effects of angiotensin receptor neprilysin inhibition by sacubitril/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients.](https://www.ncbi.nlm.nih.gov/pubmed29500454) SCI REP 2018 Mar 2; 8 (1): 3933.doi.10.1038/s41598-018-22194-z - Zijlstra E, Coester HV, Heise T, Plum-Mörschel L, Rasmussen O, Rikte T, Pedersen LK, Qvist M, Sparre T. [Injecting without pressing a button: An explanatory study of a shield-triggered injection mechanism.](https://www.ncbi.nlm.nih.gov/pubmed/29369493) DIABETES OBES METAB 2017 Dec 27. doi: 10.1111/dom.13203. (Epub ahead of print) - Hövelmann U, Bysted BV, Mouritzen U, Macchi F, Lamers D, Kronshage B, Moller DV, Heise T. [Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog.](https://www.ncbi.nlm.nih.gov/pubmed/29273578) DIABETES CARE 2017 Dec 22. doi: 10.2337/dc17-1402. (Epub ahead of print) - Engeli S, Stinkens R, Heise T, May M, Goossens GH, Blaak EE, Havekes B, Jax T, Albrecht D, Pal P, Tegtbur U, Haufe S, Langenickel TH, Jordan J. [Effect of sacubitril/valsartan on exercise-induced lipid metabolism in patients with obesity and hypertension.](https://www.ncbi.nlm.nih.gov/pubmed/29180454) HYPERTENSION 71: 70-77, 2018 - Heise T, Kaplan K, Haahr HL. [Day-to-day and within-day variability in glucose-lowering effect between insulin degludec and insulin glargine (100 U/mL and 300 U/mL): A comparison across studies.](https://www.ncbi.nlm.nih.gov/pubmed/28946756) J DIABETES SCI TECHNOL 2017 Sep 1. doi: 10.1177/1932296817731422. (Epub ahead of print) - Zijlstra E, Demissie M, Graungaard T, Heise T, Nosek L, Bode B. [Investigation of pump compatibility of fast-acting insulin aspart in subjects with type 1 diabetes.](https://www.ncbi.nlm.nih.gov/pubmed/28918652) J DIABETES SCI TECHNOL 2018; 12: 145-151 - Harris C, Forst T, Heise T, Plum-Mörschel L, Watkins E, Zhang Q, Fan L, Garhyan P, Porksen N. [Hypoglycemia risk related to double dose is markedly reduced with basal insulin peglispro versus insulin glargine in patients with type 2 diabetes mellitus in a randomized trial: IMAGINE 8.](https://www.ncbi.nlm.nih.gov/pubmed/28817342) DIABETES TECHNOL THER 19: 463-470, 2017 - Heise T, Biester T. Pharmakologische Eigenschaften des schneller wirksamen Insulins aspart (Faster-acting Insulin aspart).  Pharmacological properties of faster-acting insulin aspart (Faster-acting Insulin aspart). DIABETOLOGIE UND STOFFWECHSEL 2017 Aug 11. doi: // 10.1055/s-0043-116018. (Epub ahead of print)  - Jordan J, Tank J, Heusser K, Heise T, Wanner C, Heer M, Macha S, Mattheus M, Lund SS, Woerle HJ, Broedl UC. [The effect of empagliflozin on muscle sympathetic nerve activity in patients with type 2 diabetes mellitus.](https://www.ncbi.nlm.nih.gov/pubmed/28757109) J AM SOC HYPERTENS 2017 Jul 21. doi: 10.1016/jash.2017.07.005. (Epub ahead of print) - Davies M, Dahl D, Heise T, Kiljanski J, Mathieu C. [Introduction of similar insulins in Europe.](https://www.ncbi.nlm.nih.gov/pubmed/28608570) DIABET MED 2017 Jun 13. doi: 10.1111/dme.13400. (Epub ahead of print) - Heise T, Hövelmann U, Nosek L, Sassenfeld B, Thomsen KMD, Haahr H. [Pharmacokinetic properties of fast-acting insulin aspart administered in different subcutaneous injection regions: response to the commentary by Nuggehally R. Srinivas.](https://www.ncbi.nlm.nih.gov/pubmed/28597216) CLIN DRUG INVEST 2017 Jun 8. doi: 10.1007/s40261-017-0539-7. (Epub ahead of print) - Goldman J, Kapitza C, Pettus J, Heise T. [Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.](https://www.ncbi.nlm.nih.gov/pubmed/28537449) CURR MED RES OPIN 2017 May 24: 1-26. doi: 10.1080/03007995.1335192. (Epub ahead od print)  - Kenny HC, Rudwill F, Breen L, Salanova M, Blottner D, Heise T, Heer M, Blanc S, O'Gorman DJ. [Bed rest and resistive vibration exercise unveil novel links between skeletal muscle mitochondrial function and insulin resistance.](https://www.ncbi.nlm.nih.gov/pubmed/28500394) DIABETOLOGIA 2017 May 12. doi: 10.1007/s00125-017-4298-z. (Epub ahead of print) 浏览Profil的[发表物列表](https://www.profil.com/knowledge-center/publications?hsLang=zh)以查看我们的其他发表物。   ### 主要成就及工作经验 | 2016 -  | Lead Scientist and chair of the Board of Directors of Profil.  | | --- | --- | | 1999 - 2016 | Co-founder and CEO Science of Profil. Principal Investigator of several hundred challenging early phase studies of experimental diabetes treatments; in particular pharmacodynamic / pharmacokinetic assessments performed with the glucose clamp technique | | 2002 | Co-founder of DIEM, Institute for Evidence-Based Medicine in Cologne, Germany | | 2000 - 2002 | Clinical job on the side at the Department for Internal Medicine, St. Franziskus Hospital Cologne (Director: Prof. P.T. Sawicki) for the outpatient care of diabetic patients | | 1991 - 1999 | Scientific Associate, Clinic of Metabolic Diseases and Nutrition, Heinrich-Heine-University Düsseldorf, WHO Collaborating Center for Diabetes. Occupation at the Diabetes ward and the Endocrinology/Rheumatology ward, the out-patient clinics for diabetes, diabetic foot problems, diabetic late complications, and obesity, and at the Intensive Care Unit. In charge of numerous GCP-studies concerning insulin resistance, hypertension, obesity, and pharmacokinetic and –dynamic properties of novel insulin preparations, insulin administration forms and antidiabetic drugs |   ### 联系Tim Heise 博士 ![blank.jpg](https://info.profil.com/hs-fs/hubfs/BLUE_MOON/piktos/Icon_References.png?width=49&height=49&name=Icon_References.png) #### References We have published with the following sponsors: ![Referenzen](https://info.profil.com/hubfs/BLUE_MOON/content-bilder/Referenzen.gif "Referenzen") [View more](https://info.profil.com/knowledge-center/references?hsLang=zh) ![blank.jpg](https://info.profil.com/hs-fs/hubfs/BLUE_MOON/piktos/Icon_Certificates.png?width=44&height=49&name=Icon_Certificates.png) #### Certificates | ![13485_Zertifikatssiegel_black_A3](https://info.profil.com/hubfs/BLUE_MOON/piktos/ISO_134852016_certificate_blue.png) ISO 13485:2016 ![27001_Zertifikatssiegel](https://info.profil.com/hubfs/BLUE_MOON/piktos/ISO_27001_certificate_.png) ISO 27001 | ![9001:2015_Zertifikatssiegel](https://info.profil.com/hubfs/BLUE_MOON/piktos/ISO_9001-2015_certificate.png) ISO 9001:2015 ![9001:2015_Zertifikatssiegel](https://info.profil.com/hubfs/BLUE_MOON/piktos/BVMA_Logo_Certificate_size.png) BVMA Member | | --- | --- | ![blank.jpg](https://info.profil.com/hs-fs/hubfs/BLUE_MOON/piktos/Icon_Publications.png?width=44&height=49&name=Icon_Publications.png) #### Publications Heise T. et al., 2014. Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes. Diabetes Obes Metab. 2014; 16: 1070-1077 [View all](https://info.profil.com/knowledge-center/publications?hsLang=zh) ###### Profil Institut für Stoffwechselforschung GmbH Hellersbergstraße 9 · 41460 - Neuss, Germany Telefon +49-2131-4018-345 · marketing@profil.com [Imprint](https://www.profil.com/imprint?hsLang=zh) | [Privacy Policy](https://www.profil.com/privacy?hsLang=zh)